Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389933 | 0.89 | HTR2A (0.52) | HTR2ARETRECQLCYP19A1CYP11B2 | |
| SCHEMBL31165889 | 0.82 | HTR2A (0.73) | HTR2ARETANPEPIDO1ACP3 | |
| SCHEMBL113822 | 0.82 | HTR2A (0.73) | HTR2ARETANPEPIDO1ACP3 | |
| SCHEMBL19334608 | 0.74 | HTR2A (0.67) | HTR2ARETANPEPIDO1TSHR | |
| SCHEMBL6386269 | 0.74 | HTR2A (0.50) | HTR2ARETCYP19A1ANPEPIDO1 | |
| SCHEMBL23905793 | 0.72 | SIGMAR1 (0.42) | CYP11B2SIGMAR1IDO1TDO2 | |
| SCHEMBL7811212 | 0.71 | CYP11B2 (0.60) | HTR2ARETRECQLCYP19A1CYP11B2 | |
| SCHEMBL10642897 | 0.71 | HTR2A (0.56) | HTR2ARETANPEPIDO1ACP3 | |
| SCHEMBL6388506 | 0.70 | ADRA2A (0.44) | HTR2ACYP19A1CYP11B2SIGMAR1 | |
| SCHEMBL6385324 | 0.70 | CYP19A1 (0.40) | CYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | HTR2A 282/4885RET 1869/4885RECQL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.